These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 19451908

  • 1. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS.
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract] [Full Text] [Related]

  • 2. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J, Smith B, Courtney B, Mair M.
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract] [Full Text] [Related]

  • 3. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2009 Jun; 22(1):30-8. PubMed ID: 19209297
    [Abstract] [Full Text] [Related]

  • 4. Biodefense. Critics question proposed countermeasures agency.
    Kaiser J.
    Science; 2005 Nov 04; 310(5749):755. PubMed ID: 16272086
    [No Abstract] [Full Text] [Related]

  • 5. Concerns raised over declining antiinfectives R&D.
    Fox JL.
    Nat Biotechnol; 2003 Nov 04; 21(11):1255-6. PubMed ID: 14595340
    [No Abstract] [Full Text] [Related]

  • 6. Biodefense. House passes plan for drug, vaccine R&D.
    Kaiser J.
    Science; 2006 Oct 06; 314(5796):39. PubMed ID: 17023625
    [No Abstract] [Full Text] [Related]

  • 7. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E.
    Nat Biotechnol; 2008 Dec 06; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract] [Full Text] [Related]

  • 8. A critical tipping point.
    Zuckerman MB.
    US News World Rep; 2002 Apr 22; 132(13):72. PubMed ID: 11993366
    [No Abstract] [Full Text] [Related]

  • 9. Developing drugs for developing countries.
    Ridley DB, Grabowski HG, Moe JL.
    Health Aff (Millwood); 2006 Apr 22; 25(2):313-24. PubMed ID: 16522573
    [Abstract] [Full Text] [Related]

  • 10. An uncertain call to arms.
    Fraser CM.
    Science; 2004 Apr 16; 304(5669):359. PubMed ID: 15087509
    [No Abstract] [Full Text] [Related]

  • 11. In defence of priority review vouchers.
    Sonderholm J.
    Bioethics; 2009 Sep 16; 23(7):413-20. PubMed ID: 19659848
    [Abstract] [Full Text] [Related]

  • 12. Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.
    Javitt GH.
    J Contemp Health Law Policy; 2002 Sep 16; 19(1):37-116. PubMed ID: 12733223
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH.
    Drug Discov Today; 2005 Nov 01; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Funding agendas: has bioterror defense been over-prioritized?
    May T.
    Am J Bioeth; 2005 Nov 01; 5(4):34-44. PubMed ID: 16109694
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ganging up on the FDA.
    Stone PH.
    Natl J (Wash); 1995 Feb 18; 27(7):410-4. PubMed ID: 10140321
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.